
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst is currently in a reset year, with revenue guidance for FY26 missing consensus by 6% at the midpoint. However, incremental clarity on DOS-related ARR churn and potential retention of $22M out of a $52M pool indicate potential revenue growth in FY27. Additionally, the potential sale of certain application assets, such as VitalWare, could generate significant proceeds and support the company's financials.
Bears say
Health Catalyst is facing several near-term challenges, including a decline in revenue and profitability due to the completion of its DOS-to-Ignite migration and potential customer churn and down-selling. However, the company's long-term potential lies in its proprietary technology and data analytics, which can help address the $1 trillion in healthcare waste in the US. While the transition to Ignite has led to some pressure on the data platform, the company has already shown some traction with new platform customer signings. The risk of potential churn and down-selling highlights the need for effective execution and management of resources to drive growth and improve profitability in the future.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares